Campbell & CO Investment Adviser LLC Sells 44,931 Shares of Maximus, Inc. $MMS

Campbell & CO Investment Adviser LLC cut its holdings in shares of Maximus, Inc. (NYSE:MMS) by 92.1% in the 3rd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 3,858 shares of the health services provider’s stock after selling 44,931 shares during the period. Campbell & CO Investment Adviser LLC’s holdings in Maximus were worth $353,000 at the end of the most recent reporting period.

Several other large investors have also added to or reduced their stakes in the business. Canada Pension Plan Investment Board bought a new position in shares of Maximus in the second quarter valued at approximately $35,000. UMB Bank n.a. grew its stake in Maximus by 37.5% in the 2nd quarter. UMB Bank n.a. now owns 833 shares of the health services provider’s stock valued at $58,000 after purchasing an additional 227 shares during the period. Bayforest Capital Ltd purchased a new stake in shares of Maximus during the 2nd quarter valued at $61,000. Parkside Financial Bank & Trust raised its stake in shares of Maximus by 21.7% during the 2nd quarter. Parkside Financial Bank & Trust now owns 879 shares of the health services provider’s stock worth $62,000 after purchasing an additional 157 shares during the period. Finally, GAMMA Investing LLC boosted its holdings in shares of Maximus by 60.4% in the 2nd quarter. GAMMA Investing LLC now owns 1,174 shares of the health services provider’s stock worth $82,000 after buying an additional 442 shares during the last quarter. Institutional investors own 97.21% of the company’s stock.

Insider Buying and Selling

In related news, insider Michelle F. Link sold 4,039 shares of the company’s stock in a transaction dated Wednesday, December 3rd. The shares were sold at an average price of $86.84, for a total transaction of $350,746.76. Following the transaction, the insider directly owned 19,542 shares in the company, valued at approximately $1,697,027.28. This represents a 17.13% decrease in their position. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. 1.60% of the stock is owned by insiders.

Maximus Trading Down 0.4%

NYSE MMS opened at $98.56 on Friday. The stock has a market cap of $5.37 billion, a P/E ratio of 17.73 and a beta of 0.56. Maximus, Inc. has a fifty-two week low of $63.77 and a fifty-two week high of $100.00. The stock has a 50 day simple moving average of $88.53 and a two-hundred day simple moving average of $85.00. The company has a debt-to-equity ratio of 0.77, a quick ratio of 1.64 and a current ratio of 1.64.

Maximus (NYSE:MMS) last released its earnings results on Thursday, November 20th. The health services provider reported $1.62 earnings per share for the quarter, missing analysts’ consensus estimates of $1.63 by ($0.01). The business had revenue of $1.32 billion during the quarter, compared to analysts’ expectations of $1.34 billion. Maximus had a return on equity of 25.23% and a net margin of 5.87%.The firm’s quarterly revenue was up .2% compared to the same quarter last year. During the same period in the prior year, the company earned $1.46 earnings per share. Maximus has set its FY 2026 guidance at 7.950-8.250 EPS. On average, analysts forecast that Maximus, Inc. will post 6.15 earnings per share for the current year.

Maximus Increases Dividend

The business also recently declared a quarterly dividend, which will be paid on Monday, March 2nd. Investors of record on Friday, February 13th will be given a $0.33 dividend. This is a boost from Maximus’s previous quarterly dividend of $0.30. This represents a $1.32 dividend on an annualized basis and a yield of 1.3%. The ex-dividend date is Friday, February 13th. Maximus’s dividend payout ratio is 21.58%.

Wall Street Analysts Forecast Growth

A number of analysts have issued reports on the company. Zacks Research raised Maximus from a “hold” rating to a “strong-buy” rating in a research report on Tuesday, December 30th. Weiss Ratings reissued a “buy (b-)” rating on shares of Maximus in a report on Monday, December 29th. One investment analyst has rated the stock with a Strong Buy rating and one has given a Buy rating to the company’s stock. According to MarketBeat, the company has a consensus rating of “Strong Buy”.

Maximus Profile

Maximus, Inc (NYSE: MMS) is a global provider of government services focused on delivering health and human services programs. The company partners with federal, state, and local agencies to administer and manage programs that support individuals and families across various stages of life. Key service areas include eligibility determination and enrollment services for Medicaid, Medicare, Children’s Health Insurance Program (CHIP) and other public assistance programs, as well as call center operations, case management and program integrity solutions.